DK0912176T3 - Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression - Google Patents
Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppressionInfo
- Publication number
- DK0912176T3 DK0912176T3 DK97928260T DK97928260T DK0912176T3 DK 0912176 T3 DK0912176 T3 DK 0912176T3 DK 97928260 T DK97928260 T DK 97928260T DK 97928260 T DK97928260 T DK 97928260T DK 0912176 T3 DK0912176 T3 DK 0912176T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunosuppression
- tumors
- treatment
- acid amides
- pyridylalkynic
- Prior art date
Links
- 206010062016 Immunosuppression Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 title 1
- 230000005760 tumorsuppression Effects 0.000 title 1
- -1 pyridyl alkane Chemical class 0.000 abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19624668A DE19624668A1 (de) | 1996-06-20 | 1996-06-20 | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
PCT/EP1997/003244 WO1997048397A1 (en) | 1996-06-20 | 1997-06-20 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0912176T3 true DK0912176T3 (da) | 2003-01-13 |
Family
ID=7797502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97928260T DK0912176T3 (da) | 1996-06-20 | 1997-06-20 | Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0912176B1 (da) |
JP (1) | JP2000512652A (da) |
AT (1) | ATE224713T1 (da) |
AU (1) | AU3262497A (da) |
DE (2) | DE19624668A1 (da) |
DK (1) | DK0912176T3 (da) |
ES (1) | ES2181006T3 (da) |
PT (1) | PT912176E (da) |
WO (1) | WO1997048397A1 (da) |
ZA (1) | ZA975443B (da) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451816B1 (en) | 1997-06-20 | 2002-09-17 | Klinge Pharma Gmbh | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
JPH10338658A (ja) * | 1997-04-08 | 1998-12-22 | Hoechst Marion Roussel Kk | レチノイド作用調節剤 |
US6903118B1 (en) | 1997-12-17 | 2005-06-07 | Klinge Pharma Gmbh | Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides |
DE19756235A1 (de) * | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
DE19756261A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide |
DE19756212A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
DE19818044A1 (de) * | 1998-04-22 | 1999-10-28 | Klinge Co Chem Pharm Fab | Verwendung von Vitamin-PP-Verbindungen |
WO2000009132A1 (en) * | 1998-08-12 | 2000-02-24 | Smithkline Beecham Corporation | Calcilytic compounds |
EP1031564A1 (en) * | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
DE19908483A1 (de) * | 1999-02-26 | 2000-10-05 | Klinge Co Chem Pharm Fab | Inhibitoren der zellulären Niacinamidmononucleotid-Bildung |
DK1318837T3 (da) | 2000-08-11 | 2005-01-10 | Wyeth Corp | Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom |
KR20030031198A (ko) | 2000-09-29 | 2003-04-18 | 글락소 그룹 리미티드 | 염증 질환 치료용 모르폴린-아세트아미드 유도체 |
EP1348434A1 (en) * | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
GB0207445D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
CN101160285A (zh) | 2005-03-17 | 2008-04-09 | 辉瑞大药厂 | 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物 |
PE20071159A1 (es) | 2005-10-31 | 2007-11-30 | Schering Corp | Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina |
US8067415B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
WO2007053498A1 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
HUP0600809A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
CA2728806A1 (en) | 2008-06-24 | 2009-12-30 | Topotarget A/S | Squaric acid derivatives as inhibitors of the nicotinamide phosphoribosyltransferase |
MX2011002240A (es) | 2008-08-29 | 2011-04-05 | Topotarget As | Nuevos derivados de urea y tiourea. |
WO2011006988A1 (en) | 2009-07-17 | 2011-01-20 | Topotarget A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
AR082886A1 (es) | 2010-09-03 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones farmaceuticas que los contienen |
TW201217359A (en) | 2010-09-03 | 2012-05-01 | Forma Therapeutics Inc | Novel compounds and compositions for the inhibition of NAMPT |
PE20140011A1 (es) | 2010-09-03 | 2014-01-31 | Forma Tm Llc | Compuestos y composiciones novedosos para la inhibicion de nampt |
WO2012041873A1 (en) * | 2010-09-29 | 2012-04-05 | Intervet International B.V. | N-heteroaryl compounds |
TW201238950A (en) | 2010-11-15 | 2012-10-01 | Abbott Lab | NAMPT and rock inhibitors |
WO2012067963A1 (en) | 2010-11-15 | 2012-05-24 | Abbott Laboratories | Nampt inhibitors |
BR112013028281A2 (pt) | 2011-05-04 | 2017-01-10 | Forma Tm Llc | compostos e composições para inibição de nampt |
IN2013MN02014A (da) | 2011-05-09 | 2015-06-12 | Forma Tm Llc | |
US8975398B2 (en) | 2012-05-11 | 2015-03-10 | Abbvie Inc. | NAMPT inhibitors |
WO2013170118A1 (en) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Thiazolecarboxamide derivatives for use as nampt inhibitors |
CN104684906B (zh) | 2012-05-11 | 2017-06-09 | 艾伯维公司 | Nampt抑制剂 |
BR112014028042A2 (pt) | 2012-05-11 | 2017-06-27 | Abbvie Inc | inibidores de nampt |
US9938258B2 (en) | 2012-11-29 | 2018-04-10 | Karyopharm Therapeutics Inc. | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof |
CN108440515B (zh) | 2013-07-03 | 2022-05-03 | 卡尔约药物治疗公司 | 取代的苯并呋喃基和苯并噁唑基化合物及其用途 |
WO2015042414A1 (en) | 2013-09-20 | 2015-03-26 | Karyopharm Therapeutics Inc. | Multicyclic compounds and methods of using same |
MX2018001979A (es) | 2015-08-18 | 2019-04-25 | Karyopharm Therapeutics Inc | (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer. |
WO2017117447A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Multicyclic compounds and uses thereof |
US11638762B2 (en) | 2016-10-18 | 2023-05-02 | Seagen Inc. | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors |
WO2018086703A1 (en) | 2016-11-11 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Dihydropyridazinones substituted with phenylureas |
WO2018201087A1 (en) | 2017-04-27 | 2018-11-01 | Seattle Genetics, Inc. | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates |
JP2021512103A (ja) | 2018-01-31 | 2021-05-13 | バイエル アクチェンゲゼルシャフトBayer Aktiengesellschaft | Nampt阻害剤を含む抗体薬物複合体(adcs) |
WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
CA3157315A1 (en) | 2019-11-06 | 2021-05-14 | Yushma Bhurruth-Alcor | Cancer treatments targeting cancer stem cells |
AU2022273050A1 (en) | 2021-05-13 | 2023-11-09 | Remedy Plan, Inc. | Nampt inhbitors and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4778796A (en) * | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
JP2832979B2 (ja) * | 1988-02-15 | 1998-12-09 | 武田薬品工業株式会社 | 不飽和カルボン酸アミド誘導体 |
EP0343307A1 (en) * | 1988-05-26 | 1989-11-29 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. | 4-Piperidinealkanamine derivatives |
WO1991015484A1 (de) * | 1990-04-10 | 1991-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridine als arzneimittel |
EP0525023A1 (de) * | 1990-04-10 | 1993-02-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue pyridinester |
-
1996
- 1996-06-20 DE DE19624668A patent/DE19624668A1/de not_active Ceased
-
1997
- 1997-06-19 ZA ZA9705443A patent/ZA975443B/xx unknown
- 1997-06-20 EP EP97928260A patent/EP0912176B1/en not_active Expired - Lifetime
- 1997-06-20 DE DE69715861T patent/DE69715861T2/de not_active Expired - Lifetime
- 1997-06-20 ES ES97928260T patent/ES2181006T3/es not_active Expired - Lifetime
- 1997-06-20 AT AT97928260T patent/ATE224713T1/de active
- 1997-06-20 AU AU32624/97A patent/AU3262497A/en not_active Abandoned
- 1997-06-20 JP JP10502317A patent/JP2000512652A/ja not_active Withdrawn
- 1997-06-20 PT PT97928260T patent/PT912176E/pt unknown
- 1997-06-20 WO PCT/EP1997/003244 patent/WO1997048397A1/en active IP Right Grant
- 1997-06-20 DK DK97928260T patent/DK0912176T3/da active
Also Published As
Publication number | Publication date |
---|---|
ZA975443B (en) | 1998-02-10 |
ES2181006T3 (es) | 2003-02-16 |
DE19624668A1 (de) | 1998-02-19 |
JP2000512652A (ja) | 2000-09-26 |
DE69715861T2 (de) | 2003-06-12 |
PT912176E (pt) | 2003-01-31 |
AU3262497A (en) | 1998-01-07 |
EP0912176A1 (en) | 1999-05-06 |
WO1997048397A1 (en) | 1997-12-24 |
EP0912176B1 (en) | 2002-09-25 |
DE69715861D1 (de) | 2002-10-31 |
ATE224713T1 (de) | 2002-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0912176T3 (da) | Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression | |
TR199802651T2 (xx) | Piridilalken, Piridil-Alkin Asit Amidleri | |
TR200200068T2 (tr) | Nematisital triflüorobütenler | |
TR200102800T2 (tr) | Yeni bileşikler. | |
TR199901174T2 (xx) | Yeni heterosiklilmetil-ikameli pirazol t�revleri. | |
DE69729786D1 (de) | Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen | |
CY1107493T1 (el) | Μεθοδοι και συνθεσεις για την προληψη ανεκτικοτητας στα βρογχοδιασταλτικα | |
ATE280826T1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
DE69809726T2 (de) | Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene | |
DK0479903T3 (da) | Substituerede imidazoler og deres anvendelse som angiotensin II hæmmere | |
ATE271058T1 (de) | Mycophenol bisphosponatverbindungen | |
TR200000782T2 (tr) | Resorsinol türevleri. | |
TR199701669A1 (xx) | Deri preparasyonu i�in bile�imler. | |
DK0934309T3 (da) | Nye pyridylalkansyreamider som cytostatiske og immunosuppressive midler | |
PT1083903E (pt) | Indenopirrolocarbazoles em ponte | |
KR960702830A (ko) | 방사선 보호제로서의 N-알킬티오 폴리아민 유도체(N-Alkylthio polyaine derivatives as radioprotective agents) | |
ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
NO964238L (no) | Halofantrin-fri-base for behandling av malaria og blandinger | |
TR200002955T2 (tr) | Antitümör aktivitesi olan spisülozin bileşimleri | |
TR200101979T2 (tr) | Antidepresyon tedavisi için 5HT1 antagonistleri. | |
TR200000697T2 (tr) | İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları. | |
MX9602557A (es) | Proteinas de higado de mamifero y su uso en oncologia. | |
DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
TR199901380A2 (xx) | Di-ya da triazo-spiro$4,5] dekan t�revleri | |
DE69830044D1 (de) | Kugelförmige molekülgruppierung |